Upadacitinib
Back to search| Scientific Name: | Upadacitinib |
| Brand Name: | Rinvoq |
| Company Owner: | Not Available |
| Mechanism Of Action | Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that involves the interplay of several mediators, including the immune cells (mainly T- and B-lymphocytes) and pro-inflammatory cytokines, such as the tumour necrosis factor (TNF) , transforming growth factor (TGF) , and interleukin 6 (IL-6) . |
| Description of the Drug: | Upadacitinib is an oral Janus kinase (JAK) 1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. |
| Protein Data Bank: | Not Available |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB15091
